TOKYO, Apr 14 (Pulse News Wire) – D&M Company (189A.T) reported robust third-quarter results for the fiscal year ending May 2026, covering the period from June 1, 2025, to February 28, 2026. Revenue reached ¥1.223 billion, up ¥7.7 million percent compared to the same quarter last year.
Operating profit declined to ¥214 million, down --¥7.4 million percent, while ordinary profit increased to ¥245 million, up ¥5.9 million percent. Net income attributable to parent shareholders stood at ¥168 million, marking a rise of ¥2.5 million percent year-over-year. The company's financial position also showed improvement. Total assets grew to ¥10.45 billion, and equity rose to ¥2.260 billion, reflecting a capital adequacy ratio of ¥21.6 million percent. Despite challenges in the healthcare sector due to ongoing economic uncertainties, D&M Company maintained its strong performance through its comprehensive suite of services, including financing, consulting, and human resource support. Looking ahead, D&M Company projects revenue of ¥1.703 billion for the full fiscal year ending May 31, 2026, with operating profit expected to reach ¥200 million, ordinary profit at --¥33.2 million, and net income attributable to parent shareholders forecasted at --¥23.7 million.
The company remains confident in achieving its targets despite potential risks associated with geopolitical tensions and economic fluctuations. In the third quarter, F&I service revenues amounted to ¥567.0 million, a 1.9% percent increase from the previous year, although gross profit decreased by 3.5% percent. C&Br service revenues climbed to ¥367.3 million, up 9.7% percent, driven by stable demand for large medical equipment sales and consultancy services. HR&OS service revenues surged to ¥289.6 million, a 18.3% percent jump, bolstered by growth in recruitment and outsourcing operations. Overall, D&M Company’s diversified approach continues to drive its success, with the third-quarter performance exceeding initial forecasts across multiple metrics. The company plans to maintain its strategic focus on supporting healthcare institutions amid evolving industry conditions.
Financial results — FY2026/5 (consolidated)
| Metric | Current | YoY |
|---|---|---|
| Revenue | ¥1,223M | +7.7% |
| Operating profit | ¥214M | -7.4% |
| Net profit | ¥168M | +2.5% |
Next period forecast
Revenue
¥1,703M
+13.3%Op. profit
¥200M
-33.2%Net profit
¥151M
-31.6%Source: TDNet filing · Figures in millions of yen
🟢 Confidence: High AI-translated content.